Uber (UBER): Evaluating Valuation After Bold Entry Into Robotaxi and New Strategic Partnerships

Uber Technologies (UBER) just made headlines by partnering with Lucid Group to invest in a next-generation robotaxi initiative that could put 20,000 electric vehicles on the road over the next six years. This is more than just another tech announcement; it is a clear signal that Uber is doubling down on autonomous and electric mobility. For investors weighing up the possibilities, this move says a lot about where Uber’s management sees growth beyond the traditional ride-hailing business and hints at major shifts in both how the company operates and how markets might value it in the future.

This announcement comes shortly after several high-profile business moves, including Uber's new partnership with Best Buy to bring consumer electronics onto the Uber Eats platform and a recent fixed-income offering. Over the past year, Uber's share price has surged almost 35%, outpacing much of the market, as the company reported improved profitability and shed noncore divisions. With nearly 50% year-to-date gains and renewed momentum, the market’s enthusiasm appears fueled by the company's expanding reach and operational discipline.

With this wave of strategic news and a strong performance in the share price, investors may consider whether Uber is now attractively priced or if the market is already factoring in significant growth for the future.

Advertisement

Most Popular Narrative: 29% Overvalued

According to the most popular narrative, Uber is currently viewed as overvalued, with its market price trading well above what is justified by underlying company assumptions and discount rates.

Uber has several key products and services that could significantly impact its sales and earnings. Ride-Hailing Services remain Uber’s core revenue generator. The company continues to innovate and expand its ride-hailing services globally.

What is really powering this aggressive price target? A closer look hints at ambitious projections for both top-line growth and future profitability. Curious which business segments are expected to bring in the biggest rewards, and which key financial ratios are forecasting a tech-style premium for Uber? Unlock the full narrative for the surprising details shaping this bold valuation thesis.

Result: Fair Value of $72.92 (OVERVALUED)

Have a read of the narrative in full and understand what's behind the forecasts.

However, operational challenges such as driver dissatisfaction and heightened regulatory scrutiny could still dampen Uber’s ambitious growth story.

Find out about the key risks to this Uber Technologies narrative.

Another View: A Different Take on Value

Looking through the lens of our SWS DCF model, Uber's shares tell a very different story. This method values future cash flows, and the outcome challenges the overvalued narrative from traditional ratios. Could the market be missing something, or is optimism running too hot?

Look into how the SWS DCF model arrives at its fair value.
UBER Discounted Cash Flow as at Sep 2025
UBER Discounted Cash Flow as at Sep 2025
Stay updated when valuation signals shift by adding Uber Technologies to your watchlist or portfolio. Alternatively, explore our screener to discover other companies that fit your criteria.

Build Your Own Uber Technologies Narrative

If the perspectives above do not align with your views or you prefer hands-on analysis, it only takes a few minutes to create and test your own thesis. Do it your way.

A great starting point for your Uber Technologies research is our analysis highlighting 4 key rewards and 3 important warning signs that could impact your investment decision.

Looking for more investment ideas?

Now is the perfect time to find your next big winner. The market is full of fresh opportunities that you do not want to overlook. Use the powerful Simply Wall Street Screener and let your curiosity lead you to new possibilities across dynamic sectors and innovative trends.

  • Capture income potential by reviewing companies with reliable payouts using our dividend stocks with yields > 3% for yields above 3%.
  • Spot tomorrow’s AI breakthroughs by browsing AI penny stocks, featuring forward-thinking technology leaders changing the game.
  • Uncover great value by targeting undervalued stocks based on cash flows, which focuses on cash flows and highlights stocks that could be flying under the radar.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

New: AI Stock Screener & Alerts

Our new AI Stock Screener scans the market every day to uncover opportunities.

• Dividend Powerhouses (3%+ Yield)
• Undervalued Small Caps with Insider Buying
• High growth Tech and AI Companies

Or build your own from over 50 metrics.

Explore Now for Free

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com

Kshitija Bhandaru

Kshitija Bhandaru

Kshitija (or Keisha) Bhandaru is an Equity Analyst at Simply Wall St and has over 6 years of experience in the finance industry and describes herself as a lifelong learner driven by her intellectual curiosity. She previously worked with Market Realist for 5 years as an Equity Analyst.

About NYSE:UBER

Uber Technologies

Develops and operates proprietary technology applications in the United States, Canada, Latin America, Europe, the Middle East, Africa, and the Asia Pacific.

Very undervalued with excellent balance sheet.

Advertisement

Weekly Picks

LO
Lou_Basenese
OPTH logo
Lou_Basenese on Optimi Health ·

The Only Psychedelic Company Already Selling MDMA and Psilocybin to Real Patients, Yet Priced Like It Doesn’t Exist

Fair Value:US$1157.5% undervalued
47 users have followed this narrative
2 users have commented on this narrative
7 users have liked this narrative
WE
WealthAP
NOVO B logo
WealthAP on Novo Nordisk ·

Novo Nordisk (NVO): Is the "Easy Growth" Story Over?

Fair Value:DKK 407.7721.4% undervalued
66 users have followed this narrative
0 users have commented on this narrative
8 users have liked this narrative
VA
ValueInvestingSubstack
ZTS logo
ValueInvestingSubstack on Zoetis ·

Zoetis down -50% over the past year

Fair Value:US$92.9218.9% undervalued
22 users have followed this narrative
0 users have commented on this narrative
9 users have liked this narrative
CE
CentryResearch
LEU logo
CentryResearch on Centrus Energy ·

Centrus Energy: The Next Nuclear Bottleneck Isn't Reactors. It's Fuel.

Fair Value:US$19013.7% undervalued
24 users have followed this narrative
0 users have commented on this narrative
10 users have liked this narrative

Updated Narratives

WI
WisetoWealth
PYPL logo
WisetoWealth on PayPal Holdings ·

The Underrated Transformation of a Digital Payments Giant

Fair Value:US$90.3137.8% undervalued
1 users have followed this narrative
0 users have commented on this narrative
0 users have liked this narrative
BL
Blagget
TERA logo
Blagget on Terra Balcanica Resources ·

The C$4M Explorer Positioned to Become Europe's First Antimony Mine

Fair Value:CA$0.487.5% undervalued
1 users have followed this narrative
0 users have commented on this narrative
0 users have liked this narrative
DA
CHTR logo
david_6nroa on Charter Communications ·

Charter is undervalued - Here's why.

Fair Value:US$87.0741.6% overvalued
1 users have followed this narrative
0 users have commented on this narrative
0 users have liked this narrative

Popular Narratives

CU
MSFT logo
CubanEros on Microsoft ·

A wonderful business at reasonable price.

Fair Value:US$419.919.1% undervalued
81 users have followed this narrative
0 users have commented on this narrative
6 users have liked this narrative
OS
oscargarcia
NVDA logo
oscargarcia on NVIDIA ·

The company that went from selling GPUs to gamers to becoming the AI arms dealer of the 21st century.

Fair Value:US$28026.1% undervalued
185 users have followed this narrative
9 users have commented on this narrative
15 users have liked this narrative
BE
PYPL logo
benjamin_lvieq on PayPal Holdings ·

PayPal: PayPal Doesn't Need to Grow – It Needs to Stop Falling – A Mispriced Cash Machine With a Cannibal Buyback

Fair Value:US$6513.6% undervalued
71 users have followed this narrative
2 users have commented on this narrative
11 users have liked this narrative

Trending Discussion

DE
TDOC logo
derek_3wsdg on Teladoc Health ·

You’ve overlooked the activist investor factor. Travis Cocke’s Voss has announced 5% ownership through a 13G filing. They’ve added to that 5% since, and in doing so, have created a structural trap door for 27.42 Million Shares actively sold short. Chuck will announce lots of positives on July 29 but it’s what Voss announces shortly after that will rock the overextended Teledoc shorts. The Walmart partnership is the tip of the iceberg. The market is missing the sheer regulatory and enterprise friction of modern corporate healthcare. Teladoc isn't a "consumer app"; it is the primary digital infrastructure integrated directly into the legacy backends of Tier-1 insurance companies and fortune 500 employers, covering 105 million+ lives. Teladoc is acting as the digital top-of-funnel engine for the world's largest retailer. If Voss pushes the narrative that Teladoc is effectively the outsourced digital brain of Walmart's entire healthcare footprint, the fair value shifts from a basic health multiple to an enterprise distribution premium. Additionally , we are in a structural gold rush for high-quality, legally compliant, longitudinal medical data to train vertical healthcare AI models. Large technology hyperscalers and pharmaceutical giants cannot simply scrape the internet for this; they need structured clinical inputs. Teladoc sits on one of the largest de-identified virtual medical datasets on earth. From the activist playbook , we’ll see Voss demand the immediate creation of a Data & Diagnostics Licensing Division, transforming a legacy liability into an incredibly high-margin, pure-software data asset that requires zero human clinician hours to scale. Chuck is doing great work and deserves credi5 for the Teledoc turnaround but it will be Travis Cocke who will be responsible for a share price way beyond your $15 valuation.

1
|
0